OKYO PHARMA LTD (OKYO) Stock News

USA - NASDAQ:OKYO - GG00BMFG5F62 - Common Stock

2.65 USD

+0.26 (+10.88%)

Last: 10/27/2025, 8:00:03 PM

2.6791 USD

+0.03 (+1.1%)

After Hours: 10/27/2025, 8:00:03 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

OKYO Latest News, Press Relases and Analysis

All

Press Releases

12 days ago - By: OKYO Pharma LTD

OKYO Pharma Announces Chairman and Founder Acquires Shares

12 days ago - By: OKYO Pharma LTD

OKYO Pharma Announces Chairman and Founder Acquires Shares

a month ago - By: Stocktwits

News Image

OKYO Pharma Stock Rises After Company Outlines Development Pathway For Neuropathic Corneal Pain Drug

a month ago - By: OKYO Pharma LTD

OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain

a month ago - By: OKYO Pharma LTD

OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain

5 months ago - By: ACCESS Newswire

Goldman Small Cap Research Issues New Research Update on OKYO Pharma Limited

a year ago - By: Benzinga - Mentions: VKTX NTLA

3 Health Care Stocks Moving In Thursday's Intraday Session

3 months ago - By: OKYO Pharma LTD

OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain

3 months ago - By: OKYO Pharma LTD

OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain

3 months ago - By: Benzinga - Mentions: HBIO SRPT MEIP WINT ...

12 Health Care Stocks Moving In Thursday's Pre-Market Session

3 months ago - By: OKYO Pharma LTD

OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain

3 months ago - By: OKYO Pharma LTD

OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain

5 months ago - By: OKYO Pharma LTD

OKYO Pharma to Present at the Bio International Convention

5 months ago - By: OKYO Pharma LTD

OKYO Pharma to Present at the Bio International Convention

5 months ago - By: OKYO Pharma LTD

OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit

5 months ago - By: OKYO Pharma LTD

OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit

6 months ago - By: OKYO Pharma LTD

FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain

6 months ago - By: OKYO Pharma LTD

OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain

6 months ago - By: OKYO Pharma LTD

OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain

7 months ago - By: OKYO Pharma LTD

OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod

7 months ago - By: OKYO Pharma LTD

OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod

8 months ago - By: OKYO Pharma LTD

OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain

8 months ago - By: OKYO Pharma LTD

OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain

9 months ago - By: OKYO Pharma LTD

OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod

9 months ago - By: OKYO Pharma LTD

OKYO Pharma Announces Chairman and CEO Acquire Shares

9 months ago - By: OKYO Pharma LTD

OKYO Pharma Announces Chairman and CEO Acquire Shares

9 months ago - By: ACCESS Newswire

Goldman Small Cap Research Publishes New Research Report on OKYO Pharma Limited

9 months ago - By: OKYO Pharma LTD

OKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second Quarter

9 months ago - By: OKYO Pharma LTD

OKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second Quarter

9 months ago - By: OKYO Pharma LTD

OKYO Pharma Receives $1.4 Million in Non-Dilutive Funding

9 months ago - By: OKYO Pharma LTD

OKYO Pharma Receives $1.4 Million in Non-Dilutive Funding

a year ago - By: OKYO Pharma LTD

OKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology Conference

a year ago - By: OKYO Pharma LTD

OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference

a year ago - By: OKYO Pharma LTD

OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference

a year ago - By: OKYO Pharma LTD

OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain